Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7842206 | 0.89 | KMT2A (0.33) | MAPTALDH1A1KDM4ECYP3A4CYP2C19 | |
| SCHEMBL3662809 | 0.89 | KMT2A (0.33) | MAPTALDH1A1KDM4ECYP3A4CYP2C19 | |
| SCHEMBL3654655 | 0.87 | JAK2 (0.35) | PTGDR2MAPTALDH1A1KDM4ECYP2C19 | |
| SCHEMBL13929371 | 0.87 | KMT2A (0.34) | PTGDR2MAPTALDH1A1KDM4ECYP3A4 | |
| SCHEMBL3663350 | 0.86 | IDO1 (0.40) | ALDH1A1KDM4ESMN1; SMN2NPSR1PTGS2 | |
| SCHEMBL699507 | 0.86 | FBP1 (0.38) | MAPTKDM4EKMT2AMEN1TDP1 | |
| SCHEMBL3662827 | 0.86 | KMT2A (0.34) | PTGDR2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL13929266 | 0.86 | KMT2A (0.36) | MAPTALDH1A1KDM4ECYP2C19HPGD | |
| SCHEMBL7841390 | 0.86 | KMT2A (0.38) | PTGDR2MAPTALDH1A1KDM4EHPGD | |
| SCHEMBL4213519 | 0.85 | CNR1 (0.32) | MAPTALDH1A1KDM4ECYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421866-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076482-B2 | 3,3′-spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2235017-B1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010121995-A1 | 3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | CHEN LI | 2010-10-28 | — | — | US | disclosed |
| EP-2235017-A1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776875-B2 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | HOFFMAN-LA ROCHE INC. (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2009080488-A1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080488-A1 | SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | CHEN LI | 2009-06-25 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163512-A1 | such as 2'S,3S,4'R)-6-chloro-4'-{5-chloro-2-[1-methyl-1-(1-methyl-piperidin-4-ylcarbamoyl)-ethoxy]-phenyl}-2'-(5-fluoro-2-methyl-phenyl)spiro[3H-indole-3,3'-piperidine]-2,6'(1H)-dione, used as antiproliferative agents, especially, as anticarcinogenic agents | TOP2B, TOP2A, CCNY | PTGDR2 1288/4885PTGDR 873/4885MAPT 4856/4885 |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | PTGDR2 983/4885PTGDR 562/4885MAPT 4581/4885 |
| US-20100273819-A1 | 3,3'-Spiroindolinone Derivatives | SIK3, RB1, CCND3 | PTGDR2 1263/4885PTGDR 991/4885MAPT 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.